EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Gili Kenet iD, Beatrice Nolan iD, Bulent Zulfikar iD, Bulent Antmen iD, Peter Kampmann, Tadashi Matsushita iD, Chur-Woo You, Kateryna Vilchevska, Catherine N Bagot iD, Azizan Sharif, Flora Peyvandi iD, Guy Young iD und 8 weitere

Blood · 2024

DOI: 10.1182/blood.2023021864 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Blood, 2024. Verfasst von Gili Kenet und 19 weiteren Autor:innen. Beteiligte Einrichtung: The National Hemophilia Centre, Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Hemophilia B, Hemophilia A, Hemorrhage. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, targets antithrombin to rebalance hemostasis in people with hemophilia A or B (PwHA/B), irrespective of inhibitor status. This phase 3, open-label study evaluated the efficacy and safety of fitusiran prophylaxis in males aged ≥12 years with hemophilia A or B, with or without inhibitors, who received prior bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis. Participants continued their prior BPA/CFC prophylaxis for 6 months before switching to once-monthly 80 mg fitusiran prophylaxis for 7 months (onset and efficacy periods). Primary end point was annualized bleeding rate (ABR) in the BPA/CFC prophylaxis and fitusiran efficacy period. Secondary end points included spontaneous ABR (AsBR) and joint ABR (AjBR). Safety and tolerability were assessed. Of 80 enrolled participants, 65 (inhibitor, n = 19; noninhibitor, n = 46) were eligible for ABR analyses. Observed median ABRs were 6.5 (interquartile range [IQR], 2.2-19.6)/4.4 (IQR, 2.2-8.7) with BPA/CFC prophylaxis vs 0.0 (IQR, 0.0-0.0)/0.0 (IQR, 0.0-2.7) in the corresponding fitusiran efficacy period. Estimated mean ABRs were substantially reduced with fitusiran by 79.7% (P = .0021) and 46.4% (P = .0598) vs BPA/CFC prophylaxis, respectively. Forty-one participants (63.1%) experienced 0 treated bleeds with fitusiran vs 11 (16.9%) with BPAs/CFCs. Median AsBR and AjBR were both 2.2 with BPA/CFC prophylaxis and 0.0 in the fitusiran efficacy period. Two participants (3.0%) experienced suspected or confirmed thromboembolic events with fitusiran. Once-monthly fitusiran prophylaxis significantly reduced bleeding events vs BPA/CFC prophylaxis in PwHA/B, with or without inhibitors, and reported adverse events were generally consistent with previously identified risks of fitusiran. This trial was registered at www.ClinicalTrials.gov as #NCT03549871.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia BHemophilia AHemorrhageHumansMaleAdultMiddle AgedAdolescentYoung AdultChildRNA, Small InterferingBlood Coagulation FactorsAged

Substanzen

RNA, Small InterferingBlood Coagulation Factors

Autor:innen und Institutionen

  • The National Hemophilia Centre, Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel.
  • Department of Hematology, Children's Health Ireland at Crumlin, Dublin, Ireland.
  • Division of Pediatric Hematology-Oncology, Istanbul University Oncology Institute, Istanbul, Turkey.
  • Department of Pediatric Hematology/Oncology and Bone Marrow Transplantation Unit, Faculty of Medicine, Acibadem University, Adana Hospital, Adana, Turkey.
  • Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.

ORCID-Profile: Gili Kenet, Beatrice Nolan, Bulent Zulfikar, Bulent Antmen, Tadashi Matsushita, Catherine N Bagot, Flora Peyvandi, Guy Young, Claude Negrier, Kaan Kavakli

Zitieren

APA

Kenet, G., Nolan, B., Zulfikar, B., Antmen, B., Kampmann, P., Matsushita, T., You, C. W., Vilchevska, K., Bagot, C. N., Sharif, A., Peyvandi, F., Young, G., Negrier, C., Chi, J., Kittner, B., Sussebach, C., Shammas, F., Mei, B., Andersson, S., & Kavakli, K. (2024). Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. https://doi.org/10.1182/blood.2023021864

Vancouver

Kenet G, Nolan B, Zulfikar B, Antmen B, Kampmann P, Matsushita T, et al. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. 2024. doi:10.1182/blood.2023021864

BibTeX
@article{Kenet2024,
  author = {Kenet, Gili and Nolan, Beatrice and Zulfikar, Bulent and Antmen, Bulent and Kampmann, Peter and Matsushita, Tadashi and You, Chur-Woo and Vilchevska, Kateryna and Bagot, Catherine N and Sharif, Azizan and Peyvandi, Flora and Young, Guy and Negrier, Claude and Chi, Jiarui and Kittner, Barbara and Sussebach, Christian and Shammas, Fadi and Mei, Baisong and Andersson, Shauna and Kavakli, Kaan},
  title = {Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2023021864}
}
Kostenlos starten →